Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TTPH

Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis

Tetraphase Pharmaceuticals logo

About Tetraphase Pharmaceuticals Stock (NASDAQ:TTPH)

Key Stats

Today's Range
$2.18
$2.27
50-Day Range
$2.20
$2.20
52-Week Range
$0.56
$8.60
Volume
282,689 shs
Average Volume
932,542 shs
Market Capitalization
$15.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

Receive TTPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tetraphase Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTPH Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
TTPH_old Historical Data
10 Worst NASDAQ Biotech Stocks in the Third Quarter
See More Headlines

TTPH Stock Analysis - Frequently Asked Questions

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.32. The biopharmaceutical company earned $1.76 million during the quarter, compared to analyst estimates of $2.45 million. Tetraphase Pharmaceuticals had a negative trailing twelve-month return on equity of 210.86% and a negative net margin of 798.18%.

Tetraphase Pharmaceuticals shares reverse split on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tetraphase Pharmaceuticals investors own include Alcoa (AA), Aurinia Pharmaceuticals (AUPH), General Electric (GE), Bank of America (BAC), OPKO Health (OPK), Novavax (NVAX) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
5/07/2020
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TTPH
Fax
N/A
Employees
119
Year Founded
N/A

Profitability

Net Income
$-70,080,000.00
Net Margins
-798.18%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.38 million
Book Value
$6.68 per share

Miscellaneous

Free Float
N/A
Market Cap
$15.98 million
Optionable
Optionable
Beta
2.33
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:TTPH) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners